Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

CDK12: an emerging therapeutic target for cancer.

Lui GYL, Grandori C, Kemp CJ.

J Clin Pathol. 2018 Nov;71(11):957-962. doi: 10.1136/jclinpath-2018-205356. Epub 2018 Aug 13. Review.

PMID:
30104286
2.

Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.

Schaub FX, Dhankani V, Berger AC, Trivedi M, Richardson AB, Shaw R, Zhao W, Zhang X, Ventura A, Liu Y, Ayer DE, Hurlin PJ, Cherniack AD, Eisenman RN, Bernard B, Grandori C; Cancer Genome Atlas Network.

Cell Syst. 2018 Mar 28;6(3):282-300.e2. doi: 10.1016/j.cels.2018.03.003.

3.

Novel cooperative pathway of c-Myc and Furin, a pro-protein convertase, in cell proliferation as a therapeutic target in ovarian cancers.

Hasegawa-Minato J, Toyoshima M, Ishibashi M, Zhang X, Shigeta S, Grandori C, Kitatani K, Yaegashi N.

Oncotarget. 2017 Dec 15;9(3):3483-3496. doi: 10.18632/oncotarget.23322. eCollection 2018 Jan 9.

4.

Identification of a novel E-box binding pyrrole-imidazole polyamide inhibiting MYC-driven cell proliferation.

Mishra R, Watanabe T, Kimura MT, Koshikawa N, Ikeda M, Uekusa S, Kawashima H, Wang X, Igarashi J, Choudhury D, Grandori C, Kemp CJ, Ohira M, Verma NK, Kobayashi Y, Takeuchi J, Koshinaga T, Nemoto N, Fukuda N, Soma M, Kusafuka T, Fujiwara K, Nagase H.

Cancer Sci. 2015 Apr;106(4):421-9. doi: 10.1111/cas.12610. Epub 2015 Mar 3.

5.

Synthetic lethal screens as a means to understand and treat MYC-driven cancers.

Cermelli S, Jang IS, Bernard B, Grandori C.

Cold Spring Harb Perspect Med. 2014 Mar 1;4(3). pii: a014209. doi: 10.1101/cshperspect.a014209. Review. Erratum in: Cold Spring Harb Perspect Med. 2014 Apr;4(4). doi:10.1101/cshperspect.a023390.

6.

A high-throughput siRNA screening platform to identify MYC-synthetic lethal genes as candidate therapeutic targets.

Grandori C.

Methods Mol Biol. 2013;1012:187-200. doi: 10.1007/978-1-62703-429-6_12.

PMID:
24006065
7.

Functional genomics to identify unforeseen cancer drug targets.

Kemp CJ, Grandori C.

Future Oncol. 2013 Apr;9(4):473-6. doi: 10.2217/fon.13.26. No abstract available.

PMID:
23560369
8.

Functional genomics identifies therapeutic targets for MYC-driven cancer.

Toyoshima M, Howie HL, Imakura M, Walsh RM, Annis JE, Chang AN, Frazier J, Chau BN, Loboda A, Linsley PS, Cleary MA, Park JR, Grandori C.

Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9545-50. doi: 10.1073/pnas.1121119109. Epub 2012 May 23.

9.

MYC-driven tumorigenesis is inhibited by WRN syndrome gene deficiency.

Moser R, Toyoshima M, Robinson K, Gurley KE, Howie HL, Davison J, Morgan M, Kemp CJ, Grandori C.

Mol Cancer Res. 2012 Apr;10(4):535-45. doi: 10.1158/1541-7786.MCR-11-0508. Epub 2012 Feb 1.

10.

Gene expression signature of c-MYC-immortalized human fibroblasts reveals loss of growth inhibitory response to TGFβ.

Wang ML, Walsh R, Robinson KL, Burchard J, Bartz SR, Cleary M, Galloway DA, Grandori C.

Cell Cycle. 2011 Aug 1;10(15):2540-8. Epub 2011 Aug 1.

11.

MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT.

Zhang Z, Sun H, Dai H, Walsh RM, Imakura M, Schelter J, Burchard J, Dai X, Chang AN, Diaz RL, Marszalek JR, Bartz SR, Carleton M, Cleary MA, Linsley PS, Grandori C.

Cell Cycle. 2009 Sep 1;8(17):2756-68. Epub 2009 Sep 29.

PMID:
19652553
12.

c-Myc accelerates S-phase and requires WRN to avoid replication stress.

Robinson K, Asawachaicharn N, Galloway DA, Grandori C.

PLoS One. 2009 Jun 18;4(6):e5951. doi: 10.1371/journal.pone.0005951.

13.

NFX1 interacts with mSin3A/histone deacetylase to repress hTERT transcription in keratinocytes.

Xu M, Luo W, Elzi DJ, Grandori C, Galloway DA.

Mol Cell Biol. 2008 Aug;28(15):4819-28. doi: 10.1128/MCB.01969-07. Epub 2008 May 27.

14.

Epigenetic down-regulation of ARF expression is a selection step in immortalization of human fibroblasts by c-Myc.

Benanti JA, Wang ML, Myers HE, Robinson KL, Grandori C, Galloway DA.

Mol Cancer Res. 2007 Nov;5(11):1181-9. Epub 2007 Nov 2.

15.

Non-transcriptional control of DNA replication by c-Myc.

Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M, Galloway DA, Gu W, Gautier J, Dalla-Favera R.

Nature. 2007 Jul 26;448(7152):445-51. Epub 2007 Jun 27.

PMID:
17597761
16.

Regulation of telomerase by human papillomaviruses.

Galloway DA, Gewin LC, Myers H, Luo W, Grandori C, Katzenellenbogen RA, McDougall JK.

Cold Spring Harb Symp Quant Biol. 2005;70:209-15.

PMID:
16869756
17.

Activation by c-Myc of transcription by RNA polymerases I, II and III.

Gomez-Roman N, Felton-Edkins ZA, Kenneth NS, Goodfellow SJ, Athineos D, Zhang J, Ramsbottom BA, Innes F, Kantidakis T, Kerr ER, Brodie J, Grandori C, White RJ.

Biochem Soc Symp. 2006;(73):141-54. Review.

PMID:
16626295
18.

c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I.

Grandori C, Gomez-Roman N, Felton-Edkins ZA, Ngouenet C, Galloway DA, Eisenman RN, White RJ.

Nat Cell Biol. 2005 Mar;7(3):311-8. Erratum in: Nat Cell Biol. 2005 May;7(5):531.

PMID:
15723054
19.

Functional link between Myc and the Werner gene in tumorigenesis.

Grandori C, Robinson KL, Galloway DA, Swisshelm K.

Cell Cycle. 2004 Jan;3(1):22-5. Review.

PMID:
14657658
20.

Werner syndrome protein limits MYC-induced cellular senescence.

Grandori C, Wu KJ, Fernandez P, Ngouenet C, Grim J, Clurman BE, Moser MJ, Oshima J, Russell DW, Swisshelm K, Frank S, Amati B, Dalla-Favera R, Monnat RJ Jr.

Genes Dev. 2003 Jul 1;17(13):1569-74.

Supplemental Content

Loading ...
Support Center